Why is it important to select therapies for YourPDX testing early?

It’s helpful to select therapies early in the phase-one YourPDX functional oncology testing process to avoid delays during the phase-two, pharmacology. Certis will need to know how many test arms will be included to determine the number of orthotopic patient-derived xenograft (O-PDX) replicates to create. We enroll five fully-tumored mouse avatars in each test arm, including the control arm. By way of example: if five different therapeutic options are chosen, that is a 6-arm test (5 plus 1 control); 30 fully tumored mouse avatars would be required to conduct the test. We generally engraft 25% more mice than are needed to ensure we have enough mouse avatars when it comes time to begin dosing.